**SUPPLEMENTAL FIGURE 1.** Estimated odds ratios for categorical worsening from moderate/extreme impairment (≥4) at baseline to mild/no impairment (≤3) at week 8 (LOCF) in SDS subscales for desvenlafaxine versus placebo. \*Favors desvenlafaxine indicates smaller proportions with worsening function for desvenlafaxine versus placebo. CI, confidence interval; LOCF, last observation carried forward; SDS, Sheehan Disability Scale.

**SUPPLEMENTAL FIGURE 2.** Proportions of patients who shifted to mild/no impairment (SDS subscale score ≤3) at week 8 (LOCF) by no early improvement versus early improvement at week 4, patients with marked/extreme impairment (≥7) at baseline only. Early improvement significantly predicted functional response at week 8 (LOCF) on each subscale for all treatment groups (all *P* < .0001). LOCF, last observation carried forward; SDS, Sheehan Disability Scale.